Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 7/20 | 0.36 |
| ▸ | CA2 | P00918 | 7/20 | 0.36 |
| ▸ | CA9 | Q16790 | 5/20 | 0.36 |
| ▸ | CA12 | O43570 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5718171 | 1.00 | PPM1B (0.38) | PPM1BPTPN1PPP1CCTSHRCA1 | |
| SCHEMBL8836695 | 1.00 | PPM1B (0.38) | PPM1BPTPN1PPP1CCTSHRCA1 | |
| SCHEMBL8102462 | 1.00 | PPM1B (0.38) | PPM1BPTPN1PPP1CCTSHRCA1 | |
| SCHEMBL11907582 | 0.90 | NPC1 (0.34) | PPM1BPTPN1PPP1CCALDH1A1GAA | |
| SCHEMBL11909862 | 0.88 | — | — | |
| SCHEMBL11907282 | 0.87 | PPM1B (0.41) | PPM1BPTPN1PPP1CCALDH1A1HPGD | |
| SCHEMBL10502396 | 0.84 | ALDH1A1 (0.37) | PPM1BPTPN1PPP1CCTSHRKDM4E | |
| SCHEMBL11907446 | 0.84 | — | — | |
| SCHEMBL11908120 | 0.83 | TSHR (0.33) | TSHRALDH1A1 | |
| SCHEMBL10503552 | 0.82 | NAAA (0.39) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170217902-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2017-08-03 | — | — | US | disclosed |
| US-20170217902-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2017-08-03 | — | — | US | disclosed |
| US-9663472-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-05-30 | — | — | US | disclosed |
| US-9663472-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-05-30 | — | — | US | disclosed |
| US-9458152-B2 | Bicyclic sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2016-10-04 | — | — | US | disclosed |
| EP-2594559-B1 | PYRAZOLE COMPOUND | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2016-02-24 | — | — | EP | disclosed |
| US-9212182-B2 | Bicyclic sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212182-B2 | Bicyclic sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2015-12-15 | — | — | US | disclosed |
| WO-2014201206-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2014-12-18 | — | — | WO | disclosed |
| US-20140371201-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. | 2014-12-18 | — | — | US | disclosed |
| US-6790964-B1 | HYDROXY OR ALKOXY IN THE 5-POSITION; DECYCLIZATION OF A 5-HYDROXY-7- OXABICYCLO(4.1.0)HEPT-2-ENE-3-CARBOXYLATE WITH AN AMINE TO GIVE AMINODIOL, SULFONYLATING, REACTION WITH ALCOHOL; | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 2004-09-14 | — | — | US | disclosed |
| EP-1229022-B1 | PROCESS FOR THE PREPARATION OF 7-AZABICYCLO (4.1.0)-HEPT-3-ENE-3-CARBOXYLIC ACID ESTERS | SAGAMI CHEM RES (JP) | 2004-05-19 | — | — | EP | disclosed |
| EP-1229022-A1 | PROCESS FOR THE PREPARATION OF 7-AZABICYCLO 4.1.0]-HEPT-3-ENE-3-CARBOXYLIC ACID ESTERS | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 2002-08-07 | — | — | EP | disclosed |
| US-6403824-B2 | NEURAMINIDASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2002-06-11 | — | — | US | disclosed |
| US-20020006960-A1 | Process for the preparation fo 4,5-diamino shikimic acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-17 | — | — | US | disclosed |
| EP-1127872-A1 | Tamiflu via Diels-Alder | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-29 | — | — | EP | disclosed |
| US-5641784-A | ADENOSINE ANTAGONISTS; TREATMENT OF NERVOUS SYSTEM DISORDERS, ALZHEIMER'S DISEASE | BOEHRINGER INGELHEIM KG (DE) | 1997-06-24 | — | — | US | disclosed |
| EP-0104584-B1 | PROCESS FOR THE PREPARATION OF N-SUBSTITUTED ACRYLAMIDE | Chemische Fabrik Stockhausen GmbH (DE) | 1986-09-03 | — | — | EP | disclosed |
| US-4605740-A | Process for the production of N-substituted acrylic acid amides | CHEMISCHE FABRIK STOCKHAUSEN GMBH (DE) | 1986-08-12 | — | — | US | disclosed |
| EP-0104584-A1 | Process for the preparation of N-substituted acrylamide | Chemische Fabrik Stockhausen GmbH (DE) | 1984-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217902-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | PPM1B 2947/4885PTPN1 2801/4885PPP1CC 3120/4885 |
| US-20140371201-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | SCN7A, TRPV1, TRPV5 | PPM1B 2062/4885PTPN1 1140/4885PPP1CC 671/4885 |
| US-20020006960-A1 | Process for the preparation fo 4,5-diamino shikimic acid derivatives | NEU4, FUT4, NEU1 | PPM1B 2624/4885PTPN1 3014/4885PPP1CC 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.